PR Newswire: news distribution, targeting and monitoring
 

Heska Announces Q2 2010 Results

 
 

Company Has No Long Term Debt Outstanding

LOVELAND, Colo., July 20 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA) ("Heska" or the "Company") today reported financial results for its second quarter ended June 30, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20000622/HESKALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)

"Results exceeded our revenue and income guidance," said Robert Grieve, Heska's Chairman and CEO.  "As we have previously discussed, this quarter represented a difficult comparison as we are no longer selling our previous handheld blood analysis instrument and affiliated consumables.  Core Companion Animal Health Revenue excluding these handheld instruments and consumables increased in 2010 as compared to the prior year period.  We have been disappointed by the weak economic environment in the United States which we believe is having an impact on our instrument sales.  Despite these challenges, we paid the remaining balance on our long term debt prior to the end of our second quarter, a milestone we have been anticipating for some time."

Investor Conference Call

Management will conduct a conference call on Tuesday, July 20, 2010 at 9:00 a.m. MDT (11:00 a.m. EDT) to discuss the second quarter 2010 financial results.  To participate, dial (877) 941-6009 (domestic) or (480) 629-9770 (international); the conference call access number is 4329553.  The conference call will also be broadcast live over the Internet at http://www.heska.com.  To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software.  Telephone replays of the conference call will be available for playback until August 3, 2010.  The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international).  The webcast replay may be accessed from Heska's home page at www.heska.com until August 3, 2010.

About Heska

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results.  These statements are based on current expectations and are subject to a number of risks and uncertainties.  Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes.  In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the performance of third parties to whom Heska has granted substantial marketing rights including, but not limited to, Schering-Plough Animal Health Corporation; risks related to obtaining regulatory approval to authorize shipment of Heska's cattle vaccines; risks related to Heska's ability to maintain its listing on the NASDAQ Capital Market; uncertainties related to Heska's ability to market and sell its products successfully and economically; uncertainties related to Heska's ability to generate profits and cash flow in future periods; uncertainties related to the future success of Heska's efforts to prevent the production of non-compliant products in its OVP segment; risks related to Heska's reliance on third-party suppliers, which is significant; competition; uncertainties related to Heska's ability to maintain all regulatory compliance required to continue to manufacture and sell vaccines and pharmaceuticals; uncertainties related to the impact of transfer restrictions on Heska's stock, which were approved by Heska stockholders at Heska's Annual Meeting of Stockholders on May 4, 2010; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.

Financial Table Follows:

Consolidated Statements of Operations
In Thousands, Except per Share Amounts
(unaudited)



Three Months Ended
June 30,


Six Months Ended
June 30,


2009


2010


2009


2010

Revenue, net:



Core companion animal health

$

16,879



13,731


$

35,016


$

29,523


Other vaccines, pharmaceuticals and products


1,750



1,376



3,754



3,278


Total revenue, net


18,629



15,107



38,770



32,801















Cost of revenue


11,598



9,260



24,366



20,749















Gross profit


7,031



5,847



14,404



12,052















Operating expenses:













Selling and marketing


3,622



3,656



7,380



7,692


Research and development


405



388



851



845


General and administrative


1,994



2,010



4,146



4,210


Total operating expenses


6,021



6,054



12,377



12,747


Operating income (loss)


1,010



(207)



2,027



(695)


Interest and other expense, net


41



122



206



295


Income (loss) before income taxes


969



(329)



1,821



(990)


Income tax expense (benefit)


390



(164)



782



(495)


Net income (loss)

$

579


$

(165)


$

1,039


$

(495)














Basic net income (loss) per share

$

0.01


$

0.00


$

0.02


$

(0.01)


Diluted net income (loss) per share

$

0.01


$

0.00


$

0.02


$

(0.01)















Shares used for basic net income (loss) per share


52,012



52,166



52,012



52,163















Shares used for diluted net income (loss) per share


52,035



52,166



52,013



52,163





Balance Sheet Data
In Thousands (unaudited)




December 31,
2009


June 30,
2010

Cash and cash equivalents


$

5,400


$

5,564


Total current assets



28,493



27,495


Total assets



64,134



63,261


Line of credit



4,201



5,583


Current portion of long-term debt



381




Total current liabilities



14,107



14,124


Stockholders' equity



45,055



44,633





SOURCE Heska Corporation

Back to top

RELATED LINKS
http://www.heska.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

Featured Video

 
  • Print
  • Email
  •   RSS
  • Share it  
  • Blog it  
  • Blog Search  

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Free Investing Newsletter from Investor Uprising!

Learn to navigate the world's financial system and profit from leading companies.  

Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".

Advanced Search
Search
  
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire